These observations support the assumption that drugs targeting SIRT3 and SIRT5 should not have a deletary impact on host defenses, which would contrast with drugs targeting classical HDACs that strongly impaired innate immune defenses against infections in preclinical models and clinical settings (78–84). Here, SIRT3 is linked to infection.